Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis.

At 12 months after maintenance phase start, patients with UC treated with ustekinumab had numerically higher persistence, including persistence while corticosteroid-free and persistence while on monotherapy, than patients treated with adalimumab.